Brief: Newron Pharmaceuticals SpA Says Topline Results For ENIGMA-TRS 2 Phase III Global Study Are Expected In Q4 2026
08/12/2025 12:39
Dec 8 (Reuters) - Newron Pharmaceuticals SpA NWRN.S: NEWRON ANNOUNCES THE US INITIATION OF ITS ENIGMA-TRS 2 PHASE III GLOBAL CLINICAL STUDY WITH EVENAMIDE AS AN ADD-ON THERAPY FOR PATIENTS WITH TREATMENT-RESISTANT SCHIZOPHRENIA (TRS) NEWRON PHARMACEUTICALS SPA - TOPLINE RESULTS FOR ENIGMA-TRS 2 PHASE III GLOBAL STUDY ARE EXPECTED IN Q4 2026 Source text: ID:nBw8lc140a Further company coverage: NWRN.S ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Newron Pharmaceuticals SpA
See all newsUS FDA flags four deaths in Newron's schizophrenia drug studies (updated)
US FDA cites 4 deaths in Newron's schizophrenia drug trial hold
Brief: Newron Says Topline Data From ENIGMA-TRS 1 Expected In Q1 2027
Brief: Newron Provides Update Following Type A Meeting With The FDA
Brief: Newron Reports Pause Of Enrollment Of New Study Participants In US Centers Of ENIGMA-TRS 2 Study